Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource-limited settings

Journal of Infectious Diseases

Volumn 207, Issue SUPPL.2, 2013, Pages

  Cambiano, Valentina ^a   Bertagnolio, Silvia ^b   Jordan, Michael R ^c   Lundgren, Jens D ^d   Phillips, Andrew ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Rigshospitalet   (Denmark)

Author keywords

antiretroviral therapy; HIV; mathematical model; mortality; resource limited settings; transmitted drug resistance

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL RESISTANCE; ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE TRANSMISSION; DRUG COST; GEOGRAPHIC DISTRIBUTION; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; MORTALITY; POPULATION RESEARCH; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; VIRUS RESISTANCE;

ANTIRETROVIRAL THERAPY; HIV; MATHEMATICAL MODEL; MORTALITY; RESOURCE-LIMITED SETTINGS; TRANSMITTED DRUG RESISTANCE;

ANTI-RETROVIRAL AGENTS; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; GEOGRAPHY; HEALTH RESOURCES; HIV; HIV INFECTIONS; HUMANS; MODELS, THEORETICAL; MUTATION; POPULATION SURVEILLANCE; POVERTY; PREVALENCE; PUBLIC HEALTH; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; WORLD HEALTH ORGANIZATION;

EID: 84878285851     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit111     Document Type: Article

References (25)

1. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-10.
2. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008; 13:25-36.
3. WHO HIV/AIDS Programme. The HIV drug resistance report-2012, 2012.
4. Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of anti-retroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012; 380:1250-8.
5. Frentz D, Boucher CAB, van de Vijver DAMC. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. Aids Reviews 2012; 14:17-27.
6. Russell JS, Chibo D, Kaye MB, et al. Prevalence of transmitted HIV drug resistance since the availability of highly active antiretroviral therapy. Commun Dis Intell 2009; 33:216-20.
7. Hattori J, Shiino T, Gatanaga H, et al. Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan. Antivir Res 2010; 88:72-9.
8. Hamers RL, Wallis CL, Kityo C, et al. HIV-1 drug resistance in antire-troviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011; 11:750-9.
9. Price MA, Wallis CL, Lakhi S, et al. Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. Aids Res Hum Retrov 2011; 27:5-12.
10. Sinha S, Shekhar RC, Ahmad H, et al. Prevalence of HIV drug resistance mutation in the Northern Indian population after failure of the first line antiretroviral therapy. Curr HIV Res 2012; 10:532-8.
11. Soria J, Bull M, Mitchell C, et al. Transmitted HIV resistance to first-line antiretroviral therapy in Lima, Peru. Aids Res Hum Retrov 2012; 28:333-8.
12. Uthman OA, et al. Regimen simplification in HIV infection toward once-daily dosing and fixed-dose combinations: a meta-analysis and sequential analysis of randomized controlled trials.: 19th International AIDS Conference: Abstract no. TUPE096, 2012.
13. Blower S, Ma L, Farmer P, Koenig S. Predicting the impact of antiretro-virals in resource-poor settings: preventing HIV infections whilst controlling drug resistance. Curr Drug Targets Infect Disord 2003; 3:345-53.
14. Vardavas R, Blower S. The emergence of HIV transmitted resistance in Botswana: "When will the WHO detection threshold be exceeded?" PLOS One 2007; 5: e10981. doi:10.1371/journal.pone.0010981.
15. Baggaley RF, Garnett GP, Ferguson NM. Modelling the impact of antiretroviral use in resource-poor settings. PLOS Med 2006; 3:e124.
16. Blower S, Bodine E, Kahn J, McFarland W. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS 2005; 19:1-14.
17. Blower S, Farmer P. Predicting the public health impact of antiretrovi-rals: preventing HIV in developing countries. AIDScience 2003; 3:1-7.
18. Tobias RL. The president's emergency plan for AIDS relief: US five-year global HIV/AIDS strategy. 2004.
19. Wagner BG, Blower S. Universal access to HIV treatment versus universal 'Test and Treat': transmission, drug resistance & treatment costs. PLOS One 2012; 5: doi:10.1371/journal.pone.0010981.
20. Hoare A, Kerr SJ, Ruxrungtham K, et al. Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia. PLOS One 2010; 5:e10981.doi: 10.1371/journal.pone.0010981.
21. Phillips AN, Pillay D, Garnett G, et al. Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings. AIDS 2011; 25:843-50.
22. Walensky RP, Weinstein MC, Yazdanpanah Y, et al. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. AIDS 2007; 21:973-82.
23. Ciaranello AL, Lockman S, Freedberg KA, et al. First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS 2011; 25:479-92.
24. Wittkop L, Gunthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11:363-71.
25. Hamers RL, Schuurman R, Sigaloff KCE, et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis 2012; 12: 307-17.